LAGUNA HILLS, Calif., May 3, 2007 (PRIME NEWSWIRE) -- Alacrity Biosciences, Inc., a biopharmaceutical company focused on meeting unmet needs in ophthalmic diseases, today announced that clinical data from an independent pilot study using 0.025% doxycycline eye drops to treat dry eye patients in the Controlled Adverse Environment model will be presented at the Association for Research and Vision in Ophthalmology (ARVO) Meeting.
